Nancy Chang | |
|---|---|
| 唐南珊 | |
 Nancy Chang, 2012 | |
| Born | 1950 (age 73–74) |
| Alma mater | National Tsing Hua University (BS) Brown University (BA) Harvard University (PhD) |
| Known for | Xolair |
| Awards | Biotechnology Heritage Award |
| Scientific career | |
| Fields | Biotechnology, Biochemistry |
| Institutions | Tanox |
Chang Tang Chang (born 1950), née Tang Nanshan (Chinese: 唐南珊; pinyin: Táng Nánshān), is a biochemist who cofounded Tanox in 1986 to address medical needs in the areas of allergy, asthma, inflammation and diseases affecting the human immune system.[1] Tanox took an innovative approach in developing an asthma drug that focused on the allergy-related basis of asthma, Xolair. In June 2003, the U.S. Food and Drug Administration (FDA) approved Xolair, the first biotech product cleared for treating those with asthma related to allergies. Tanox was also active in the development of TNX-355, an antibody for the treatment of HIV/AIDS.[2][3] In 2007, Tanox was sold to Genentech for $919 million. Chang grew Tanox from an idea to a substantial publicly traded company, doing innovative science.[1] Following her success with Tanox, she has become an angel investor in health-care entrepreneurships and performs philanthropic work in community health-education projects.[4]
| External videos | |
|---|---|
 | |
 Nancy Chang, "Do the things you really wanted to do, that really matters to you, because then all the hardships become irrelevant.", Science History Institute |
- ^ a b "Dr. Nancy Chang, 2009". Mays Business School, Center for New Ventures and Entrepreneurship, Texas A&M University. Archived from the original on 2013-06-24.
- ^ "Nancy Chang, Taiwanese-Born Co-Founder of Tanox: Immigrant entrepreneur profile". America.gov Archive. 2008-05-14. Archived from the original on 2012-10-20.
- ^ "Nancy Chang (CEO Interview)". The Wall Street Transcript: In Depth Interviews for Investors. 2004-10-26.
- ^ Cite error: The named reference
CHFwas invoked but never defined (see the help page).